Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/8/2025

Treatment of Hemochromatosis-Associated Arthritis

Introduction to Hemochromatosis Arthropathy

  • Arthropathy affects 45-57% of hemochromatosis patients, commonly presenting as the first manifestation of disease before other systemic symptoms develop 1, 2
  • Typical distribution involves the 2nd and 3rd metacarpophalangeal joints (46.9%), ankles (69.3%), and hips (56.8%), with earlier age of onset than primary osteoarthritis 1, 2
  • Radiographic features include joint space narrowing, exuberant osteophytes, subchondral cysts, and chondrocalcinosis in 50% of cases 1, 2
  • The arthropathy can develop even during maintenance phlebotomy therapy, distinguishing it from other iron-related complications 1, 2

Primary Treatment: Iron Removal for Systemic Disease

  • Initiate weekly therapeutic phlebotomy immediately, removing 450-500 mL of blood per session until serum ferritin reaches 50 μg/L 3, 4
  • Continue lifelong maintenance phlebotomy 2-6 times per year to maintain ferritin between 50-100 μg/L 3, 4
  • Phlebotomy prevents progression of liver disease, cardiac complications, and diabetes, which account for the majority of hemochromatosis-related mortality 3, 5

Symptomatic Management of Arthropathy

  • Analgesics and NSAIDs are the mainstay of medical management for pain control 1, 2
  • Joint replacement surgery (hip and knee arthroplasty) is ultimately required for end-stage arthropathy 1, 2
  • Patients with hemochromatosis have significantly increased risk of requiring hip replacement (HR 2.77) and knee replacement (HR 2.14) compared to controls 1, 2

Dietary and Lifestyle Modifications

  • Avoid iron supplements and iron-fortified foods entirely 3, 4, 6
  • Avoid supplemental vitamin C, especially during iron depletion phase, as it accelerates iron mobilization and increases oxidative stress 3, 4, 6
  • Limit red meat consumption and restrict alcohol intake during iron depletion 3, 4, 6

Monitoring and Prognosis

  • Arthropathy symptoms significantly affect quality of life and often progress despite optimal iron management 1, 2
  • Monitor for rapid progression to cartilage loss, which is characteristic of hemochromatosis arthropathy 1, 2
  • Patients with cirrhosis require lifelong HCC screening every 6 months regardless of iron depletion status 3, 7

REFERENCES

3

Management of Hemochromatosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Initial Treatment Recommendations for Hemochromatosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025